Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$118.09

-2.04 (-1.70%)

12:10
12/17/19
12/17
12:10
12/17/19
12:10

Alnylam price target raised to $155 from $145 at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on Alnylam Pharmaceuticals and raised his price target on the shares to $155 from $145 after the company reported "positive" Phase III ILLUMINATE-A data on lumasiran in primary hyperoxaluria type 1. Tenthoff said he is "confident" in the treatment getting approval in the U.S. by year end 2020 and in Europe in 2021 and he forecasts lumasirin sales of $8M in 2020 and $85M in 2021. The analyst also noted that ONPATTRO and GIVLAARI launches are "progressing" to drive 2020 sales.

  • 04

    Feb

ALNY Alnylam
$118.09

-2.04 (-1.70%)

11/25/19
STFL
11/25/19
NO CHANGE
Target $136
STFL
Buy
Alnylam one of few mid-caps with 'plausible large-cap aspirations,' says Stifel
Stifel analyst Paul Matteis raised his price target on Alnylam shares to $136 from $126 citing earlier than expected Givosiran approval, higher than anticipated pricing and "promising advancements" in the company's early stage pipeline. A major theme of the company's analyst day was Alnylam's confidence in pursuing larger, non-orphan indications, said Matteis, who also noted that 2019 "was framed as a peak operating loss year" although no guidance was given during the event. The analyst, who sees a "compelling case" for Alnylam being "one of the few mid-caps with plausible large-cap aspirations," keeps a Buy rating on the stock.
11/25/19
BMOC
11/25/19
NO CHANGE
Target $143
BMOC
Outperform
Alnylam price target raised to $143 from $138 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam to $143 and kept his Buy rating after its R&D Day highlighted the company's commercial and pipeline plans. With Lumasiran Phase 3 trial data expected next month and his estimated "likely approval" for the drug in late-2020, the analyst also adds its projected revenue to his model, assigning an 80% probability-of-success to the program while also citing Alnylam's global Onpattro expansion driving further top-line growth.
11/22/19
NOMU
11/22/19
NO CHANGE
Target $62
NOMU
Reduce
Alnylam should be sold on 'unwarranted' strength, says Nomura Instinet
Nomura Instinet analyst Christopher Marai recommends selling shares of Alnylam Pharmaceuticals into the recent strength, which he says is "unwarranted." While the early approval moves of Givlaari moves initial sales estimates up one quarter, the "limited opportunity" in acute hepatic porphyria "ultimately does little to our valuation estimates," Marai tells investors in a research note. Further, the analyst point out Givlaari's approval is actually more than six months late, as the FDA did not accept the initial surrogate endpoint path proposed by Alnylam. In addition, further strength in the shares is likely to trigger a "dilutive financing event into what looks like a difficult 2020," contends the analyst. He keeps a Reduce rating on Alnylam with a $62 price target.
11/21/19
BMOC
11/21/19
NO CHANGE
Target $138
BMOC
Outperform
Alnylam price target raised to $138 from $128 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam to $138 and kept his Outperform rating after yesterday's approval of Givlaari came nearly 3 months ahead of its February 2020 PDUFA data. The analyst notes that while he already modeled a 100% probability of success, his raised price target reflects a one-quarter sales contribution pull forward as well as the higher price point of $575K/year vs. $450K he forecast.

TODAY'S FREE FLY STORIES

10:35
01/20/20
01/20
10:35
01/20/20
10:35
General news
Taking an "irrationally bullish" view of U.S. and global stock markets »

Taking an…

09:30
01/20/20
01/20
09:30
01/20/20
09:30
General news
Oil Action: Front-month WTI futures are up 0.7% »

Oil Action: Front-month…

07:00
01/20/20
01/20
07:00
01/20/20
07:00
General news
FX Update: All quiet on the forex front »

FX Update: All quiet on…

06:40
01/20/20
01/20
06:40
01/20/20
06:40
General news
FX Action: USD-JPY has gone into narrow-range mode »

FX Action: USD-JPY has…

AMRC

Ameresco

$19.78

-0.1 (-0.50%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
Ameresco management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

HRB

H&R Block

$24.48

-0.48 (-1.92%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
H&R Block management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

MSM

MSC Industrial

$76.89

-1.58 (-2.01%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
MSC Industrial management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 29

    Jan

03:30
01/20/20
01/20
03:30
01/20/20
03:30
General news
FX Action: USD-CAD ebbed fractionally lower »

FX Action: USD-CAD ebbed…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
FX Update: The dollar has seen modest weakness »

FX Update: The dollar has…

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:33
01/19/20
01/19
16:33
01/19/20
16:33
Periodicals
Tesla closer to opening first European factory with property deal, Reuters says »

Tesla has agreed to buy a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

JPM

JPMorgan

$138.15

0.89 (0.65%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

16:28
01/19/20
01/19
16:28
01/19/20
16:28
Periodicals
JPMorgan to acquire former BNP building in Paris, Bloomberg reports »

JPMorgan (JPM) is buying…

JPM

JPMorgan

$138.15

0.89 (0.65%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 25

    Feb

  • 14

    Apr

BAC

Bank of America

$34.70

-0.03 (-0.09%)

16:25
01/19/20
01/19
16:25
01/19/20
16:25
Periodicals
CEO tells FT Bank of America aims to 'double' slice of U.S. retail business »

Bank of America can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 15

    Apr

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.